APXZF (Carasent AB (publ)) Piotroski F-Score: 7 (As of Jun. 29, 2026) — 17% Above Median


APXZF Carasent AB (publ) APXZF
80 GF Score
Price $0.15
GF Value $0.18
! 3 Warning Signs
View Full Analysis

What is Carasent AB (publ) Piotroski F-Score?

Carasent AB (publ) APXZF 80 Piotroski F-Score is 7 as of Jun. 29, 2026, which is 17% above its 10-year median of 6.00. GuruFocus rates APXZF with a GF Score™ of 80/100 and a GF Value™ of $0.18. The stock has 3 warning signs investors should review. Among 650 Healthcare Providers & Services companies, Carasent AB (publ) ranks better than 88.92% on this metric.

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Carasent AB (publ) has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Carasent AB (publ)'s Piotroski F-Score or its related term are showing as below:

APXZF' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 6   Max: 8
Current: 7

During the past 13 years, the highest Piotroski F-Score of Carasent AB (publ) was 8. The lowest was 2. And the median was 6.

Carasent AB (publ)  (OTCPK:APXZF) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Carasent AB (publ) Piotroski F-Score Related Terms


Carasent AB (publ) Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Carasent AB (publ)'s Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carasent AB (publ) Piotroski F-Score Chart

Carasent AB (publ) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 5.00 3.00 6.00 7.00

Carasent AB (publ) Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 6.00 5.00 7.00 7.00

APXZF vs VEEV, BTSG, TEM: Piotroski F-Score Comparison

For the Health Information Services subindustry, Carasent AB (publ)'s Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Carasent AB (publ) Piotroski F-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Carasent AB (publ)'s Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Carasent AB (publ)'s Piotroski F-Score falls into.


APXZF
80GF Score
Carasent AB (publ) APXZF
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -0.577 + 1.506 + 3.126 + 0.316 = $4.37 Mil.
Cash Flow from Operations was 1.341 + 0.263 + 2.217 + 4.605 = $8.43 Mil.
Revenue was 8.679 + 8.77 + 10.068 + 9.703 = $37.22 Mil.
Gross Profit was 7.359 + 7.487 + 8.244 + 8.207 = $31.30 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(103.851 + 110.587 + 105.158 + 101.254 + 98.944) / 5 = $103.9588 Mil.
Total Assets at the begining of this year (Mar25) was $103.85 Mil.
Long-Term Debt & Capital Lease Obligation was $1.68 Mil.
Total Current Assets was $20.99 Mil.
Total Current Liabilities was $13.30 Mil.
Net Income was -0.543 + -0.193 + -2.206 + -0.295 = $-3.24 Mil.

Revenue was 6.283 + 6.31 + 7.168 + 8.407 = $28.17 Mil.
Gross Profit was 5.352 + 5.389 + 6 + 7.101 = $23.84 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(105.212 + 99.227 + 102.837 + 97.614 + 103.851) / 5 = $101.7482 Mil.
Total Assets at the begining of last year (Mar24) was $105.21 Mil.
Long-Term Debt & Capital Lease Obligation was $2.67 Mil.
Total Current Assets was $30.77 Mil.
Total Current Liabilities was $11.24 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Carasent AB (publ)'s current Net Income (TTM) was 4.37. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Carasent AB (publ)'s current Cash Flow from Operations (TTM) was 8.43. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=4.371/103.851
=0.04208915

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-3.237/105.212
=-0.03076645

Carasent AB (publ)'s return on assets of this year was 0.04208915. Carasent AB (publ)'s return on assets of last year was -0.03076645. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Carasent AB (publ)'s current Net Income (TTM) was 4.37. Carasent AB (publ)'s current Cash Flow from Operations (TTM) was 8.43. ==> 8.43 > 4.37 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=1.678/103.9588
=0.01614101

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=2.668/101.7482
=0.02622159

Carasent AB (publ)'s gearing of this year was 0.01614101. Carasent AB (publ)'s gearing of last year was 0.02622159. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=20.988/13.303
=1.57768924

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=30.771/11.235
=2.7388518

Carasent AB (publ)'s current ratio of this year was 1.57768924. Carasent AB (publ)'s current ratio of last year was 2.7388518. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Carasent AB (publ)'s number of shares in issue this year was 73.65. Carasent AB (publ)'s number of shares in issue last year was 74.775. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=31.297/37.22
=0.84086513

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=23.842/28.168
=0.84642147

Carasent AB (publ)'s gross margin of this year was 0.84086513. Carasent AB (publ)'s gross margin of last year was 0.84642147. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=37.22/103.851
=0.35839809

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=28.168/105.212
=0.26772611

Carasent AB (publ)'s asset turnover of this year was 0.35839809. Carasent AB (publ)'s asset turnover of last year was 0.26772611. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+1+0+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Carasent AB (publ) has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 7 mean?
Carasent AB (publ) (APXZF) has a Piotroski F-Score of 7 as of Jun. 29, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Carasent AB (publ) and its competitors. This is 17% above median its historical median of 6.00. Over the past decade, Carasent AB (publ)'s Piotroski F-Score has ranged from 2.00 to 8.00. According to the industry distribution chart, Carasent AB (publ) ranks #72 out of 650 companies in the Healthcare Providers & Services industry, placing it in the top 11.1%.
Is Carasent AB (publ)'s Piotroski F-Score too high?
Carasent AB (publ)'s current Piotroski F-Score of 7 is 17% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 8.00. The Healthcare Providers & Services industry median Piotroski F-Score is 5.00. Carasent AB (publ)'s value of 7 is 40% above this industry median. Based on the distribution chart, Carasent AB (publ) ranks #72 out of 650 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Carasent AB (publ) has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Carasent AB (publ)'s Piotroski F-Score compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Carasent AB (publ) ranks #72 out of 650 companies for Piotroski F-Score. This places Carasent AB (publ) in the top 11% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Carasent AB (publ)'s value of 7 is 40% above this benchmark. Historically, Carasent AB (publ)'s own Piotroski F-Score has ranged from 2.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Carasent AB (publ) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Healthcare Providers & Services company?
The median Piotroski F-Score among Healthcare Providers & Services companies is 5.00, based on 650 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carasent AB (publ)'s current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Carasent AB (publ) and its competitors. For the Healthcare Providers & Services industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carasent AB (publ)'s current Piotroski F-Score is 7, which is 17% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carasent AB (publ) stock overvalued right now?
Carasent AB (publ) (APXZF) has a current Piotroski F-Score of 7. The stock's GF Value™ is $0.18, compared to a current price of $0.15 — trading 16.7% below its estimated fair value. The current Piotroski F-Score is 7, which is 17% above median its 10-year median of 6.00 and 40% above the Healthcare Providers & Services industry median of 5.00. Carasent AB (publ)'s overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Carasent AB (publ) (APXZF), the current Piotroski F-Score is 7 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carasent AB (publ) (APXZF) Overvalued in 2026?

Based on GuruFocus' analysis, Carasent AB (publ) stock appears to be undervalued. The current stock price of $0.15 is trading 16.7% below its estimated GF Value™ of $0.18.

Key valuation signals for APXZF:

  • Piotroski F-Score: 7 (17% above median its 10-year median of 6.00)
  • GF Value™: $0.18 vs. price of $0.15 (16.7% below fair value)
  • GF Score™: 80/100 with 3 warning signs
  • Industry Position: 40% above the Healthcare Providers & Services median (#72 of 650)

No single metric tells the full story. See the APXZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Carasent AB (publ) Business Description

Other Exchanges CARA:SwedenE0C:Germany
Address Nellickevagen 24C, Gothenburg, NOR, 412 63
Carasent AB (publ) Formerly Carasent AB is a comprehensive provider of cloudbased EHR solutions and platform services for various organizations within the healthcare sector. With Webdoc as the main product, the group offers a broad ecosystem of services, including solutions for patient communication and business intelligence. Geographically, the company operates in the Nordic region and Germany. It derives maximum revenue from Nordic Region. The solutions provides by the group are: Webdoc; Metodika; Medrave; HPI plustoo; Ad Curis; Ad Opus; Webcur; Data-AL; and Data-Cur.
80GF Score

Get the complete analysis for APXZF

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price
$0.18
GF Value